Open Label Trial to Assess Iressa in Prostate Cancer Patients

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Prostate Cancer

Treatments: Drug: Gefitinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00635856

1839US/0040

Details and patient eligibility

About

A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prostate cancer diagnosis
• no evidence of metastasis
• Age 18 or older

Exclusion criteria

• Prior chemotherapy for recurrent prostate cancer
• Radiotherapy completed within 28 days of starting the study
• Incomplete healing from prior cancer or other major surgery